Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia

Reuters

02/05

Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia

Mirxes Holding Co. Ltd., through its wholly-owned subsidiary Mirxes International Holding Limited, has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD. The joint venture will focus on the research, development, commercialization, and regulatory approval of cancer early detection and other nucleic acid-based tests in Malaysia. Mirxes International Holding Limited will hold a 40% stake in the new company, while Xeraya will hold 60%. Both parties have agreed to contribute a total of approximately US$5 million in proportion to their respective equity interests. Additionally, on December 15, 2025, Mirxes Holding Co. Ltd. entered into a strategic partnership with N Health, a member of the Bangkok Dusit Medical Services (BDMS) Group, aiming to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. This collaboration is expected to enhance early cancer detection and improve patient outcomes across Thailand and the wider region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12016351), on February 05, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609201713"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609201713\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609201713?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609201713","market":"fut","top_or_hot":-1,"title":"Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mirxes Holding Co. Ltd., through its wholly-owned subsidiary Mirxes International Holding Limited, has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD. The joint venture will focus on the research, development, commercialization, and regulatory approval of cancer early detection and other nucleic acid-based tests in Malaysia. Mirxes International Holding Limited will hold a 40% stake in the new company, while Xeraya will hold 60%. Both parties have agreed to contribute a total of approximately US$5 million in proportion to their respective equity interests. Additionally, on December 15, 2025, Mirxes Holding Co. Ltd. entered into a strategic partnership with N Health, a member of the <a href=\"https://laohu8.com/S/BDULF\">Bangkok Dusit</a> Medical Services (BDMS) Group, aiming to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. This collaboration is expected to enhance early cancer detection and improve patient outcomes across Thailand and the wider region.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12016351), on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 17:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mirxes Holding Co. Ltd., through its wholly-owned subsidiary Mirxes International Holding Limited, has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD. The joint venture will focus on the research, development, commercialization, and regulatory approval of cancer early detection and other nucleic acid-based tests in Malaysia. Mirxes International Holding Limited will hold a 40% stake in the new company, while Xeraya will hold 60%. Both parties have agreed to contribute a total of approximately US$5 million in proportion to their respective equity interests. Additionally, on December 15, 2025, Mirxes Holding Co. Ltd. entered into a strategic partnership with N Health, a member of the <a href=\"https://laohu8.com/S/BDULF\">Bangkok Dusit</a> Medical Services (BDMS) Group, aiming to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. This collaboration is expected to enhance early cancer detection and improve patient outcomes across Thailand and the wider region.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12016351), on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7dR0fR:1","article_id":"2609201713","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609201713","pubTimestamp":1770283875,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mirxes Holding Co. Ltd., through its wholly-owned subsidiary Mirxes International Holding Limited, has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD. The joint venture will focus on the research, development, commercialization, and regulatory approval of cancer early detection and other nucleic acid-based tests in Malaysia. Mirxes International Holding Limited will hold a 40% stake in the new company, while Xeraya will hold 60%. Both parties have agreed to contribute a total of approximately US$5 million in proportion to their respective equity interests. Additionally, on December 15, 2025, Mirxes Holding Co. Ltd. entered into a strategic partnership with N Health, a member of the Bangkok Dusit Medical Services  Group, aiming to introduce advanced microRNA  cancer screening solutions to Thailand. This collaboration is expected to enhance early cancer detection and improve patient outcomes across Thailand and th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02629":"MIRXES-B"},"translate_title":"Mirxes与Xeraya成立合资企业在马来西亚开发癌症诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02629":0.9},"content_text":"Mirxes Forms Joint Venture With Xeraya to Develop Cancer Diagnostics in Malaysia\n    \n\n        Mirxes Holding Co. Ltd., through its wholly-owned subsidiary Mirxes International Holding Limited, has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD. The joint venture will focus on the research, development, commercialization, and regulatory approval of cancer early detection and other nucleic acid-based tests in Malaysia. Mirxes International Holding Limited will hold a 40% stake in the new company, while Xeraya will hold 60%. Both parties have agreed to contribute a total of approximately US$5 million in proportion to their respective equity interests. Additionally, on December 15, 2025, Mirxes Holding Co. Ltd. entered into a strategic partnership with N Health, a member of the Bangkok Dusit Medical Services (BDMS) Group, aiming to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. This collaboration is expected to enhance early cancer detection and improve patient outcomes across Thailand and the wider region.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12016351), on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}